TESARO, Inc.s in-depth stock price analysis indicates that the stock price has rallied 37.37% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 110.53% . Looking at the past 52 week period, the stock price is up at 404.35% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of TESARO, Inc. has a positive value of 205.43 compared to overall market. TESARO, Inc. (NASDAQ:TSRO) has climbed 10.87% in the past week and advanced 16.37% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 9.97% and the outperformance has advanced to 14.29% for the last 4 weeks period.
TESARO, Inc. (NASDAQ:TSRO) stock ended Friday session in the red zone in a volatile trading. The stock closed down 4.89 points or 2.62% at $182.02 with 1,065,394 shares getting traded. Post opening the session at $185.92, the shares hit an intraday low of $181.23 and an intraday high of $185.99 and the price was in this range throughout the day. The company has a market cap of $9,722 million and the number of outstanding shares has been calculated to be 53,412,407 shares. The 52-week high of TESARO, Inc. (NASDAQ:TSRO) is $192 and the 52-week low is $31.
TESARO Inc Last issued its quarterly earnings results on Nov 3, 2016. The company reported $-1.98 EPS for the quarter, missing the analyst consensus estimate by $ -0.07. Analyst had a consensus of $-1.91. The company had revenue of $3.73 million for the quarter, compared to analysts expectations of $4.39 million. The companys revenue was up 4187.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.66 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.TESARO Inc was Downgraded by Leerink Partners to Mkt Perform on Feb 10, 2017. TESARO Inc was Initiated by Morgan Stanley to Overweight on Jan 13, 2017. Company shares were Reiterated by FBR & Co. on Dec 27, 2016 to Outperform, Raises Price Target to $ 151 from a previous price target of $133 .
Company has reported several Insider transactions to the SEC, on Jan 3, 2017, Martin H. Jr. Huber (SVP & Chief Medical Officer) sold 190 shares at 136.26 per share price.On Dec 14, 2016, Edward C English (VP of Finance and Admin.) sold 10,000 shares at 128.75 per share price.On Sep 1, 2016, Jeffrey H. Hanke (Executive VP, R&D and CSO) sold 29,166 shares at 86.04 per share price.
Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Companys product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts.